# NCT01631552 (NCT01631552)

> Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01631552
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Gilead Sciences
- Conditions: Gastric Adenocarcinoma; Esophageal Cancer; Hepatocellular Carcinoma; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Ovarian Epithelial Cancer; Carcinoma Breast Stage IV; Hormone-refractory Prostate Cancer; Head and Neck Cancers- Squamous Cell; Renal Cell Cancer; Urinary Bladder Neoplasms; Cervical Cancer; Endometrial Cancer; Glioblastoma Multiforme; Triple Negative Breast Cancer; Pancreatic Cancer
- Interventions: Sacituzumab Govitecan-hziy (SG)
- Enrollment: 515
- Primary outcome: Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events
- Primary outcome: Percentage of Participants Who Permanently Discontinued Sacituzumab Govitecan-hziy (SG) Due to Any Adverse Events, Excluding Adverse Events Leading to Death
- Primary outcome: Percentage of Participants Who Required Dose Interruption Due to Any Adverse Events
- Primary outcome: Objective Response Rate (ORR) by Independent Central Review (ICR)
- Primary outcome: Objective Response Rate by Local Assessment

## Commentary we found

- Podcasts: 4
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct01631552